Efficacy of hydrocolloid dressing for prophylactic use of hand-foot skin reaction induced by multi targeted kinase inhibitors: a phase III self-controlled study

Conditions

Colorectal cancer,Gastrointestinal Stromal Tumor,Hepatocellular carcinoma

Ryu A, Zenda S, Shimizu Y, Takashima A, Tsutsumida A, Takahashi A, Arai M, Morizane C, Yamaguchi T, Takagi Y, Mashiko T, Miyaji T, Kawaguchi T, Yamazaki N.

2026-06-23

10.1007/s00520-026-10902-9

The efficacy of hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: A phase 3 randomized self-controlled study, J-SUPPORT 1701 APRON trial.

Atsuo Takashima, Asako Ryu, Sadamoto Zenda, Michiko Arai, Yusuke Takagi et al. (15 authors)

Journal of Clinical Oncology2023-06-01

10.1200/jco.2023.41.16_suppl.12107

Hydrocolloid dressing as a prophylactic use for hand–foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study

Sadamoto Zenda, Asako Ryu, Atsuo Takashima, Michiko Arai, Yusuke Takagi et al. (15 authors)

BMJ Open2020-10-017 citations

10.1136/bmjopen-2020-038276

Interventions

In addition to the standard care of moisturizing, attach a hydrocolloid dressing for 1 month from the start of multi-kinase inhibitor therapy. the standard care of moisturizing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically confirmed colorectal cancer, GIST, or hepatocellular carcinoma 2)Unresectable advanced or recurrent colorectal cancer, GIST, hepatocellular carcinoma 3)Patients who will start either regorafenib or sorafenib, regardless of previous therapy 4)Age of 20 years and older 5)Performance status (PS) of 0 to 2 6)Patients without cognitive impairment and capable of linguistic communication 7)Without the skin lesions judged to be difficult to evaluate skin symptoms in the sole

Exclusion criteria

Exclusion criteria: 1)Mental disease or psychiatric symptoms that interferes with daily life and judged to be difficult to participate in the study

Design outcomes

Primary

Measure	Time frame
Proportion of grade 2 or higher hand-foot syndrome (only sole)	—

Countries

Japan

Contacts

Public ContactAsako Ryu

National Cancer Center Hospital Nursing department

asryu@ncc.go.jp03-3542-2511

Outcome results

None listed